EFM
ADMA icon

E Fund Management’s ADMA Biologics ADMA Stock Holding History

E Fund Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$255K Sell
30,456
-2,441
-7% -$22.3K 0.01% 416
2026
Q1 		$296K Buy
+32,897
New +$519K 0.01% 397
2025
Q2 		$541K Buy
29,683
+8,811
+42% +$180K 0.03% 218
2025
Q1 		$414K Sell
20,872
-15,597
-43% -$270K 0.02% 246
2024
Q4 		$625K Buy
36,469
+11,351
+45% +$214K 0.03% 194
2024
Q3 		$502K Buy
25,118
+8,120
+48% +$126K 0.03% 195
2024
Q2 		$190K Sell
16,998
-15,243
-47% -$128K 0.01% 295
2024
Q1 		$213K Buy
32,241
+3,181
+11% +$17.4K 0.01% 333
2023
Q4 		$131K Sell
29,060
-3,069
-10% -$11.4K 0.01% 297
2023
Q3 		$115K Sell
32,129
-6,484
-17% -$25K 0.01% 277
2023
Q2 		$142K Sell
38,613
-17,090
-31% -$63.3K 0.01% 290
2023
Q1 		$184K Buy
55,703
+14,327
+35% +$49.5K 0.01% 309
2022
Q4 		$161K Buy
41,376
+1,518
+4% +$4.68K 0.01% 311
2022
Q3 		$97K Buy
+39,858
New +$95.6K 0.01% 328

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

E Fund Management's ADMA Position: Q2 2026 in Review

E Fund Management reduced its ADMA Biologics (ADMA) stake by 7.4% in Q2 2026, selling an estimated $22.3K and leaving 30,456 shares worth $255K. The position accounts for 0.01% of the portfolio, ranked #416.

E Fund Management first reported a position in ADMA in Q3 2022 and has held it in 14 quarters since. The position peaked at $625K in Q4 2024. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • E Fund Management held 30,456 shares of ADMA Biologics worth $255K as of Q2 2026.
  • E Fund Management sold 2,441 ADMA Biologics shares in Q2 2026, an estimated $22.3K.
  • ADMA Biologics made up 0.01% of E Fund Management's portfolio in Q2 2026, its #416 holding.
  • E Fund Management first reported a position in ADMA Biologics in Q3 2022 and has held it in 14 quarters since.
  • E Fund Management's ADMA Biologics position peaked at $625K in Q4 2024.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.